Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid‐Lowering Drugs in HIV‐Infected Individuals and Impact on Myocardial Infarction

This publication has 24 references indexed in Scilit:

• Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
  New England Journal of Medicine, 2007
• Lipid Abnormalities During Saquinavir Soft-Gel???Based Highly Active Antiretroviral Therapy
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
• Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice
  Journal of Infection, 2004
• Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999–2001
  HIV Medicine, 2004
• Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial
  The Journal of Infectious Diseases, 2003
• Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
  AIDS, 2003
• Older HIV-positive patients in the era of highly active antiretroviral therapy
  AIDS, 2003
• Comorbid Conditions, Treatment, and Health Maintenance in Older Persons with Human Immunodeficiency Virus Infection in New York City
  Clinical Infectious Diseases, 2002
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
  Clinical Infectious Diseases, 2000